Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

304

10.17650/1726-9776-2009-5-4-68-73

REVIEW

ОБЗОР

РОЛЬ БЕВАЦИЗУМАБА В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО ПОЧЕЧНО-КЛЕТОЧНОГО РАКА

Алексеев

Б. Я.

Russian Federation

byalekseev@mail.ruКалпинский

А. С.

Russian Federation

byalekseev@mail.ruКаприн

А. Д.

Russian Federation

byalekseev@mail.ruКостин

А. А.

Russian Federation

byalekseev@mail.ru

МНИОИ им. П.А. ГерценаФГУ РНЦР, Москва

30122009

68730508201405082014

https://oncourology.abvpress.ru/oncur/article/view/304

Роль бевацизумаба в лечении метастатического почечно-клеточного рака

1. Cohen H., McGovern F. Renal cell carcinoma. N Engl J Med 2005;353:3477—90. 2. Keane T., Gillatt D., Evans C. P., Tubaro A. Current and future trends in treatment of renal cancer. Eur Urol 2007;Suppl 6: 374—84.

Cohen H., McGovern F. Renal cell carcinoma. N Engl J Med 2005;353:3477—90. 2. Keane T., Gillatt D., Evans C. P., Tubaro A. Current and future trends in treatment of renal cancer. Eur Urol 2007;Suppl 6: 374—84.

3. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2008.

Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2008.

4. Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071—6.

Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071—6.

5. De Mulder P.H.M., Patard J.-J., Szczylik C. et al. Current status of targeted therapy in metastatic renal cell carcinoma. Eur Urol 2007;Suppl 6:665—71.

De Mulder P.H.M., Patard J.-J., Szczylik C. et al. Current status of targeted therapy in metastatic renal cell carcinoma. Eur Urol 2007;Suppl 6:665—71.

6. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983—1993. Semin Oncol 1995;22:42—60.

Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983—1993. Semin Oncol 1995;22:42—60.

7. Ljungberg B., Hanbury D.C., Kuczyk M.A. et al. Guidelines on renal cell cancer. European Association of Urology, 2009.

Ljungberg B., Hanbury D.C., Kuczyk M.A. et al. Guidelines on renal cell cancer. European Association of Urology, 2009.

8. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408—17.

Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408—17.

9. Stadler W.M., Huo D., George C. et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracilbased regimens for metastatic renal cancer. J Urol 2003;170:1141—5.

Stadler W.M., Huo D., George C. et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracilbased regimens for metastatic renal cancer. J Urol 2003;170:1141—5.

10. Coppinn C., Porzsolt F., Awa A. et al. Cochrane Database Syst Rev 2005:CD001425.

Coppinn C., Porzsolt F., Awa A. et al. Cochrane Database Syst Rev 2005:CD001425.

10.

11. Motzer R.J., Masumdar M., Bacic J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8): 2530—40.

Motzer R.J., Masumdar M., Bacic J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8): 2530—40.

11.

12. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289—96.

Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289—96.

12.

13. Mulders P. Continued progress in treatment of advanced renal cell carcinoma: an update on the role of Sunitinib. Eur Urol 2008;Suppl 7:579—84.

Mulders P. Continued progress in treatment of advanced renal cell carcinoma: an update on the role of Sunitinib. Eur Urol 2008;Suppl 7:579—84.

13.

14. Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(4):82—7.

Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(4):82—7.

14.

15. Ravaud A., Wallerand H., Culine S. et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008;54(2):315—25. 16. Patard J.-J. New treatment options for renal cell cancer — critical evaluation. Eur Urol 2008; Suppl 7:443—6.

Ravaud A., Wallerand H., Culine S. et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008;54(2):315—25. 16. Patard J.-J. New treatment options for renal cell cancer — critical evaluation. Eur Urol 2008; Suppl 7:443—6.

15.

17. Patard J.-J. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur Urol Suppl 2008;7:601—9.

Patard J.-J. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur Urol Suppl 2008;7:601—9.

16.

18. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115—24.

Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115—24.

17.

19. Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356: 125—34.

Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356: 125—34.

18.

20. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271—81.

Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271—81.

19.

21. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma. A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449—56.

Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma. A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449—56.

20.

22. Patard J.-J., Rioux-Leclercq N., Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006;49:633—43.

Patard J.-J., Rioux-Leclercq N., Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006;49:633—43.

21.

23. Avastin prescribing information. Available at http://www.gene.com/gene/products/infor mation/oncology/avastin/insert.jsp

Avastin prescribing information. Available at http://www.gene.com/gene/products/infor mation/oncology/avastin/insert.jsp

22.

24. Yang J.C., Haworth L., Sherry R.M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427—34.

Yang J.C., Haworth L., Sherry R.M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427—34.

23.

25. Hainsworth J.D., Sosman J.A., Spigel D.R. et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889—96.

Hainsworth J.D., Sosman J.A., Spigel D.R. et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889—96.

24.

26. Bukowski R.M., Kabbinavar F.F., Figlin R.A. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536—41.

Bukowski R.M., Kabbinavar F.F., Figlin R.A. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536—41.

25.

27. Escudier B., Pluzanska A., Koralewski P. et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma. A randomised, double-blind phase III trial. Lancet 2007;370:2103—11.

Escudier B., Pluzanska A., Koralewski P. et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma. A randomised, double-blind phase III trial. Lancet 2007;370:2103—11.

26.

28. Melichar B., Koralewski P., Ravaud A. et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19: 1470—6.

Melichar B., Koralewski P., Ravaud A. et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19: 1470—6.

27.

29. Mickisch G.H., Escudier B., Gore M. et al. Costs of managing side effects using first-line bevacizumab plus lower-dose interferon-α2a in patients with metastatic renal cell carcinoma in Germany, France, and UK. 2009 Genitourinary Cancers Symposium. Abstr 312.

Mickisch G.H., Escudier B., Gore M. et al. Costs of managing side effects using first-line bevacizumab plus lower-dose interferon-α2a in patients with metastatic renal cell carcinoma in Germany, France, and UK. 2009 Genitourinary Cancers Symposium. Abstr 312.

28.

30. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma. An overview of toxicity and dosing strategies. Oncologist 2008;13(10):1084—96.

Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma. An overview of toxicity and dosing strategies. Oncologist 2008;13(10):1084—96.

29.

31. Escudier B. J., Ravaud A., Bracarda S. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in subgroups of patients (pts) with metastatic renal cell carcinoma (mRCC). 2008 Genitourinary Cancers Symposium. Abstr 358.

Escudier B. J., Ravaud A., Bracarda S. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in subgroups of patients (pts) with metastatic renal cell carcinoma (mRCC). 2008 Genitourinary Cancers Symposium. Abstr 358.

30.

32. Escudier B.J., Bellmunt J., Negrier S. et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferonα2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27:15. Abstr 5020.

Escudier B.J., Bellmunt J., Negrier S. et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferonα2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27:15. Abstr 5020.

31.

33. Rini B.I., Halabi S., Rosenberg J.E. et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Proc ASCO Genitourinary Cancers Symposium 2008. Abstr 350.

Rini B.I., Halabi S., Rosenberg J.E. et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Proc ASCO Genitourinary Cancers Symposium 2008. Abstr 350.

32.

34. Rini B.I., Halabi S., Rosenberg J. et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 2009;27(18). LBA5019.

Rini B.I., Halabi S., Rosenberg J. et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 2009;27(18). LBA5019.

33.

35. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer [v.1.2009]. Available at http://www.nccn.org/professionals/physician_ gls/PDF/kidney.pdf

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer [v.1.2009]. Available at http://www.nccn.org/professionals/physician_ gls/PDF/kidney.pdf

34.

36. Merchan J.R., Liu G., Fitch T. et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. Proc ASCO J Clin Oncol 2007;25:5034.

Merchan J.R., Liu G., Fitch T. et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. Proc ASCO J Clin Oncol 2007;25:5034.

35.

37. Medioni J., Banu E., Helley D. et al. Salvage therapy with bevacizumab—sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma. A case series. Eur Urol 2009;56(1):1—236.

Medioni J., Banu E., Helley D. et al. Salvage therapy with bevacizumab—sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma. A case series. Eur Urol 2009;56(1):1—236.

36.

38. Feldman D.R., Kondagunta G.V., Ronnen E.A. et al.Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). Proc ASCO J Clin Oncol 2007;25:5099.

Feldman D.R., Kondagunta G.V., Ronnen E.A. et al.Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). Proc ASCO J Clin Oncol 2007;25:5099.